Status:
UNKNOWN
Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
Lead Sponsor:
Danish HIV Research Group
Collaborating Sponsors:
Rigshospitalet, Denmark
Hvidovre University Hospital
Conditions:
HIV-Associated Lipodystrophy Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological al...
Eligibility Criteria
Inclusion
- Antiretroviral naïve patients
- HIV-1 infection as documented by a licensed HIV-1 antibody ELISA.
- Fulfilling the criteria for starting antiretroviral therapy.
- Ability to understand and provide written informed consent.
Exclusion
- Women being pregnant or breast-feeding.
- Fertile women using no safe contraception.
- Patients with active intravenous drug use.
- Abuse of alcohol, which in the opinion of the treating physician will reduce the patient´s ability to follow a therapeutic regimen and evaluations of the protocol.
- Ongoing medical treatment, which has a clinically significant interaction with lopinavir, ritonavir or efavirenz.
- Creatinine \> 200 mmol/l.
- ALT or AST \> 5 times upper normal value (200U/l).
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
November 1 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00135460
Start Date
June 1 2003
End Date
November 1 2007
Last Update
March 14 2006
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Infectious Diseases, Hvidovre University Hospital
Hvidovre, Copenhagen, Denmark, 2650
2
Department of Infectious Diseases, Aalborg Hospital
Aalborg, Denmark
3
Department of Infectious Diseases, Aarhus University Hospital
Aarhus, Denmark, 8200
4
Department of Infectious Diseases, Rigshospitalet
Copenhagen, Denmark, 2100